Expertise in rare diseases
Our new corporate image ad focuses on our diverse expertise in rare disease communications. Published in Healthcare Marketing's special "Brand management for Orphan Drugs."
Here are the indications in full: Alpha-1 antitrypsin deficiency (A1AT deficiency), achondroplasia (ACH), acquired thrombotic thrombocytopenic purpura (aTTP), cold aglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), late infantile neuronal ceroid lipofuscinosis (CLN2), Duchenne muscular dystrophy with nonsense mutation (DMD NM), hereditary angioedema (HAE), Fabry disease, Gaucher disease, Pompe disease, mucopolysaccharidoses (MPS), lung disease caused by non-tuberculous mycobacteria (NTM-LD), phenylketonuria (PKU), primary immunodeficiencies (PDI), secondary immunodeficiencies (SID). Learn more about our expertise on orphan drugs and give us a call.
Want to see the whole ad?
Please click on image ad.
Here you can order the special "Brand Management for Orphan Drugs" from Healthcare Marketing.